AI-generated analysis. Always verify with the original filing.
Enzon Pharmaceuticals, Inc. entered into the Eleventh Amendment to the Section 382 Rights Agreement on March 23, 2026, extending the Final Expiration Date to noon, New York City time, on March 26, 2026. The company effected a 1-for-100 reverse stock split of its common stock effective 4:30 p.m. Eastern Time on March 24, 2026, to facilitate the anticipated merger with Viskase Companies, Inc.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On March 23, 2026, Enzon Pharmaceuticals, Inc. (the “ Company ”) entered into the Eleventh Amendment to the Section
. To the extent required by Item 3.03, the disclosure set forth in Item 5.03 is incorporated herein by reference. Item 5.03 Amendments to Articles of Incorporat
Regulation FD Disclosure. On March 24, 2026, Enzon issued a press release relating to the Reverse Stock Split. A copy of the press release is attached as Exhibi
Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 3.1* Certificate of Amendment to the Amended and Restated Certificate of Incorporation of E
Material Agreement